Video Title: The Longevity Drug Scientists Are Excited About (Not Rapamycin)
Channel: Siim Land
Speakers: Siim Land (assumed, as it's a single-speaker video from the channel)
Duration: 00:06:27
Introduction
This video explores the research on SGLT2 inhibitors as potential longevity drugs, contrasting them with metformin. The speaker analyzes studies examining the effects of these medications on mortality and lifespan, both in humans and mice.
Key Takeaways
SGLT2 inhibitors show significant promise for longevity: A 2024 study of half a million UK individuals showed a 36% lower association with mortality for those taking SGLT2 inhibitors, compared to other drugs. This benefit seems independent of blood sugar reduction.
Metformin's role in longevity is less clear: While often touted as a longevity drug, studies show mixed results. A reassessment of a 2014 study even suggests increased mortality in some cases. Metformin did not extend the lifespan of mice in the ITP program.
SGLT2 inhibitors impact various longevity pathways: Unlike metformin, which primarily lowers blood sugar, SGLT2 inhibitors exhibit broader systemic effects, stimulating longevity pathways like AMPK, PGC1 alpha, and autophagy, while lowering mTOR signaling.
SGLT2 inhibitors show positive effects in various patient groups: Studies show that SGLT2 inhibitors reduce cardiovascular mortality in diabetic patients with heart failure, reduce hospitalization for heart failure in non-diabetics, and improve cardiovascular outcomes in patients without diabetes and with heart failure.
Cost and side effects are considerations: SGLT2 inhibitors are significantly more expensive than metformin ($400/month vs $20/month). Both medications have potential side effects. SGLT2 inhibitors have been associated with increased risk of genital infections.
